{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:17:56Z","timestamp":1790032676438,"version":"4.0.1"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>\n                      The study aimed to analyze the long-term outcomes of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA.FAPi dimer therapy in individuals diagnosed with radioiodine-resistant (RAI-R) follicular cell-derived thyroid cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 73 patients with RAI-R follicular thyroid carcinoma who had undergone multiple lines of previous treatments were included. Following [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTA.SA.FAPi positron emission tomography\u2013computed tomography scan, among the 73 patients, 65 received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA.FAPi dimer monotherapy with a median activity of 5.5 GBq per cycle at 8-week intervals. The remaining eight patients underwent tandem [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\/[\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTAGA.FAPi dimer therapy, consisting of a median of two cycles of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA.FAPi dimer followed by one cycle of [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTAGA.FAPi dimer, also at 8-week intervals. The primary endpoint included progression-free survival (PFS) and overall survival (OS). Secondary endpoints included PERCIST criteria response assessment and safety assessment according to Common Terminology Criteria for Adverse Events (V5.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We enrolled 37 female and 36 male patients, with a mean age of 54.3 years (range: 27\u2009\u2212\u200980 years). The patients received a median cumulative activity of 22.2 GBq (range, 4 GBq\u201355.5 GBq) of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA-FAPi dimer over one to nine cycles, with a median of three cycles. Among 73 patients, 20 died and 16 deaths were due to thyroid cancer. Nineteen patients experienced disease progression, with an estimated median PFS of 29 months [CI 14\u201334 months]. The estimated median OS was 32 months [CI 21\u201340 months]. Four patients (5.4%) encountered grade III anemia, primarily linked to bone metastasis in three cases and neck tumor mass bleed in one. Grade III thrombocytopenia occurred in three patients (4%). No grade III renal or hepatotoxicity was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      In this study, [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA.FAPi dimer therapy showed promising safety and efficacy in aggressive, radioiodine-resistant thyroid cancer, achieving a median PFS and OS of 29 and 32 months, respectively, with manageable adverse events. Confirmation of our findings is needed from prospective clinical trials comparing [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTAGA.FAPi dimer therapy to other treatments.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2024.0229","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T10:01:59Z","timestamp":1737972119000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [\n                    <sup>177<\/sup>\n                    Lu]Lu-DOTAGA.FAPi Dimer Therapy"],"prefix":"10.1177","volume":"35","author":[{"given":"Sanjana","family":"Ballal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Prasad","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roesch","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2014TRIGA, Johannes Gutenberg University, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal R.","family":"Chandekar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2014TRIGA, Johannes Gutenberg University, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shakir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-4444","authenticated-orcid":false,"given":"Shipra","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2014TRIGA, Johannes Gutenberg University, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3431"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0502"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00102"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/618985"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70215-8"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174172"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265215"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264544"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05132-y"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0008"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06404-z"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040521"},{"issue":"6","key":"e_1_3_5_19_2","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time","volume":"11","author":"Moon ES","year":"2021","unstructured":"Moon ES, , Ballal S, , Yadav MP, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging, 2021; 11(6):476\u2013491.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061889"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121212"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0412"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016142043"},{"key":"e_1_3_5_25_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Publish Date: November 27 2017."},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05656-x"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2024.0229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2024.0229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2024.0229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:53:28Z","timestamp":1782388408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2024.0229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1089\/thy.2024.0229"],"URL":"https:\/\/doi.org\/10.1089\/thy.2024.0229","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}